Control drug group:Paxlovid
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine
Conditions
Corona Virus Disease 2019 (COVID-19)Novel Coronavirus Pneumonia (COVID-19)
Phase 3
A Multicenter, Single-Blind, Randomized, Controlled Clinical Study Evaluating the Efficacy and Safety of JT001 (VV116) Compared to Paxlovid for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants with Mild to Moderate COVID-19
Active, not recruitingChiCTR2200057856
Start: 2022-04-04Updated: 2023-11-21
A Multi-Center Single-Blind, Randomized, Controlled Trial Evaluating the SARS-CoV-2 Rebound rate after full-course treatment of JT001 (VV116) Compared to Paxlovid for the Early Treatment of Mild to Moderate Coronavirus Disease 2019 (COVID-19)
Active, not recruitingChiCTR2200066811
Start: 2022-12-20Updated: 2024-02-05